Bioanalytical and Methodological Challenges in the Evaluation of Fetal
            <i>Cannabis</i>
            Exposure

Silva, Jefferson Pereira; Yonamine, Maurı́cio

doi:10.4155/bio-2018-0055

Cited by 3 publications

(5 citation statements)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, biosample analysis can alleviate challenges in interpreting selfreported data and unmeasured secondhand or coexposure. [27][28][29] collection in recreational users.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

“…In addition to user-reported data, it is essential to collect biological samples from which objective measures of cannabis exposures can be derived. Indeed, biosample analysis can alleviate challenges in interpreting self-reported data and unmeasured secondhand or coexposure 27–29. collection in recreational users.…”

Section: Introductionmentioning

confidence: 99%

“…Meconium, the first faecal matter passed by the newborn, has emerged as the gold standard for assessing long-term gestational exposure. Meconium begins to form from 12 to 16 weeks gestation and accumulates until birth 27 29 34. To address the need for contemporary Canadian cohorts to collect robust data on maternal and infant cannabis exposures, we report here the methodology for a pilot study assessing the feasibility of developing a more extensive prospective pregnancy and birth cohort on gestational and postnatal cannabis use.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cannabis Use in Pregnancy and Downstream effects on maternal and infant health (CUPiD): a protocol for a birth cohort pilot study

et al. 2022

View full text Add to dashboard Cite

IntroductionCannabis use in pregnancy and post partum is increasing. Accessibility to cannabis has expanded due to the legalisation of cannabis in Canada. Therefore, there is a critical need to monitor the impact of cannabis on pregnancy outcomes and infant neurodevelopment. This pilot study will assess the feasibility of modern recruitment and data collection strategies adapted to the current cannabis environment and inform the design of a multicentre prospective birth cohort.Methods and analysisWe will establish a pregnancy and birth cohort of 50 cannabis users and 50 non-users recruited before delivery. We will follow the participants at regular visits from recruitment to 12 weeks post partum. Participants will provide demographic and socioeconomic data, report their cannabis use patterns, and provide biological samples. Biological samples include maternal and infant urine and blood, breastmilk/chestmilk, cord blood, cord tissue, placenta and meconium. All samples will be processed and stored at −80°C until analysis by immunoassay or liquid chromatography-tandem mass spectrometry to determine the presence of cannabis metabolites. In addition, partners will be invited to provide additional socioeconomic and substance use data.Ethics and disseminationEthics was obtained from Ottawa Health Science Network Research Ethics Board through Clinical Trials Ontario (3791). Our findings will be published in peer-reviewed journals, presented at scientific conferences and shared broadly with patients, healthcare decision-makers, and project partners online and through social media.Trial registration numberNCT05309226.Cite Now

show abstract

“…Indeed, biosample analysis can alleviate challenges in interpreting selfreported data and unmeasured secondhand or coexposure. [27][28][29] collection in recreational users.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis Use in Pregnancy and Downstream effects on maternal and infant health (CUPiD): a protocol for a birth cohort pilot study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[30][31][32] Biospecimen analysis offers a more objective strategy, and can also alleviate challenges related to unmeasured second-hand or coexposure. [33][34][35] Biospecimen collection, storage, and analysis are costly, however, and there have been few epidemiological studies in pregnancy where cannabis use has been confirmed by biospecimen analysis.…”

Section: Cannabis Use In Pregnancymentioning

confidence: 99%

The Effects of Cannabis on Female Reproductive Health Across the Life Course

Corsi

Murphy

Cook

2021

Cannabis and Cannabinoid Research

View full text Add to dashboard Cite

Introduction: Cannabis is commonly used for its medicinal and therapeutic benefits and is also widely used as a recreational drug. Cannabis use has been increasing in Canada, including among Canadian women of reproductive age. Post-legalization, further increases in cannabis use are expected due to increased availability and lowered perceptions of harm. Although cannabinoids are well known for their effects on the central and peripheral nervous systems, endocannabinoid receptors have also been characterized throughout the female reproductive tract. Cannabinoids may affect many aspects of female reproductive health, including fertility, pregnancy outcomes with neonatal implications, and menopause. Purpose: To provide a comprehensive review of trends in cannabis use among women and review the impact of cannabis across the female reproductive lifespan. Methods: We searched PubMed and Cochrane Library databases using keywords and MeSH terms. Included studies reported the potential impact of cannabinoids on female fertility, pregnancy, transmission to breast milk, neonatal outcomes, and menopause. Results: The existing literature is primarily concentrated on the effect of cannabis use in pregnancy and breastfeeding, with little exploration of its impact on fertility and in later life. Studies are limited in number, with small sample sizes, and are hampered by methodological challenges related to confounding and other potential biases. Conclusions: There remain critical gaps in the literature about the potential risks of cannabis use, particularly in vulnerable populations, including pregnant women, women who are breastfeeding, and their infants. Given the rise in the prevalence of cannabis use, new, robust investigations into the consequences of cannabis exposure on female reproductive health are needed.

show abstract

“…The most important psychoactive phytocannabinoid is the delta-9-tetrahydrocannabinol (delta9THC), a partial agonist of the endocannabinoids receptors CBr1 and CBr2, the ativation of which generates central and peripheral effects [17][18][19][20][21]. The concentration of delta9THC varies in the diferent strains of cannabis (6% to 20%), and due to its physicochemical properties (small molecular size and lipophilic nature) has high distribution and transport capacity in the human body, quickly crossing the transplacental membranes [2,[22][23][24]. It is estimated that onethird of delta9THC plasma concentration crosses the fetoplacental barriers exposing the fetuses of cannabis using mothers during the prenatal period.…”

Section: Cannabis Cannabinoids and Endocannabinoid Systemmentioning

confidence: 99%

Cannabis “in utero”: the fetus as a compulsive consumer

Ciampo

2019

ijmsci

View full text Add to dashboard Cite

Cannabis sativa, a plant known for millennia for its hallucinogenic and medicinal effects, contains widely consumed psychoactive substances worldwide, with increasing numbers among adolescents and adults, including pregnant women. Due to its potential adverse effects on users, it is of fundamental importance to know and disseminate the harm caused to humans in order to reduce the consumption of this drug. This article presents a review of the physiological and pharmacological characteristics of psychoactive substances present in cannabis, their actions on the endocannabinoid system and the placenta. It also highlights the main clinical repercussions that can occur with the fetus and, in the long run, with children whose mothers used cannabis during pregnancy.

show abstract

Bioanalytical and Methodological Challenges in the Evaluation of Fetal Cannabis Exposure

Cited by 3 publications

References 18 publications

Cannabis Use in Pregnancy and Downstream effects on maternal and infant health (CUPiD): a protocol for a birth cohort pilot study

Cannabis Use in Pregnancy and Downstream effects on maternal and infant health (CUPiD): a protocol for a birth cohort pilot study

The Effects of Cannabis on Female Reproductive Health Across the Life Course

Cannabis “in utero”: the fetus as a compulsive consumer

Contact Info

Product

Resources

About